Senior Advisor

Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge. April 10, 2026 From designing drugs with a simple text prompt to running experiments guided by extended reality, a new wave of agentic AI is transforming the modern lab. Its editors discuss the latest autonomous systems accelerating biological discovery. In business deals, Gilead Sciences has acquired Tubulis in a transaction worth up to $5 billion, strengthening the buyer's position in antibody-drug conjugates for cancer. Correspondingly, Eli Lilly and Biogen are each making billion-dollar-plus bets, acquiring Centessa, a sleep disorder drug developer, and Apellis, known for its work in immunology and rare diseases. Its episode rounds out by unpacking the dynamic obesity drug market, where intensifying competition from Novo Nordisk's Wegovy pill is prompting Lilly to temper the 2026 sales outlook for its oral obesity drug, Foundayo. Listed below are links to the GEN stories referenced in this episode of Touching Base:

Lilly wakes up sleep market with $6.3B Centessa buy to challenge Takeda. March 31, 2026 | In the buyout, Eli Lilly picks up Centessa Pharmaceuticals' lead asset cleminorexton, which could go toe-to-toe with Takeda's oveporexton, currently under FDA review with a decision expected in the third quarter. Looking to further expand its expertise beyond the cardiometabolic and neurology arenas, Eli Lilly is taking over Centessa Pharmaceuticals and its pipeline of sleep disorder drugs - a move that could put the pharma in direct competition with Takeda. Under the terms of the acquisition agreement, announced Tuesday morning, Lilly will snap up Centessa for $38 per share or $6.3 billion upfront. The pharma has also offered a contingent value right that entitles stockholders to $9 more per share if the deal hits certain milestones, including one of two FDA approvals before a certain period of time lapses. This contingent offer could add $1.5 billion more to the total buyout value. Lilly and Centessa expect to close the transaction in the third quarter of 2026. The boards of directors of both companies have approved the deal. At the heart of the acquisition agreement is Centessa's lead asset cleminorexton, an oral orexin receptor 2 (OX2R) agonist being trialed for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Orexin is a key neuropeptide that regulates the sleep-wake cycle, according to the biotech's website, in turn promoting wakefulness. Drugs that activate this pathway could help address excessive daytime sleepiness as well as improve attention, cognition and fatigue. In April 2025, Centessa released Phase 1 data showing that a 5-mg oral dose of cleminorexton delayed sleep by an average of 37.9 minutes compared to 15.3 minutes in placebo recipients, resulting in a "statistically significant" treatment effect of 22.6 minutes, the biotech said at the time. This readout "reinforces ORX750 as a potentially best-in-class OX2R agonist relative to competitors," Leerink analysts wrote an April 7, 2025 note. Analysts at BMO Capital Markets said Centessa's orexin receptor agonist has "best-in-class" potential for narcolepsy, putting the company in a strong position in the $15 billion market. April 7, 2025 With the Centessa pickup, Lilly will go toe-to-toe with Takeda, which is far ahead in the narcolepsy race with its late-stage oveporexton, also an OX2R agonist. In July 2025, Takeda announced that oveporexton significantly improved excessive daytime sleepiness, attention, quality of life, functioning and cataplexy in two Phase 3 studies. The FDA accepted Takeda's approval submission for the candidate last month, with a decision out in the third quarter of this year. Also in the narcolepsy game is Alkermes, which in November last year announced that its own OX2R agonist alixorexton aced Phase 2 and would move into late-stage development. The drug improved wakefulness and eased daytime sleepiness in patients with narcolepsy type 2, according to results presented at the time. Alixorexton's Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2. November 13, 2025 Aside from cleminorexton, Lilly will also come into possession of Centessa's broader pipeline of OX2R agonists, which includes additional preclinical assets with therapeutic potential "across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions," the pharma said Tuesday. Tristan is BioSpace 's senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. He can be reached at [email protected], [email protected] or on LinkedIn.

Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38.00 per share in cash plus contingent value rights worth up to $9.00 per share, valuing the deal at approximately $6.3 billion upfront with potential additional payments of $1.5 billion. The upfront consideration represents a 40.5% premium to Centessa's 30-day volume-weighted average share price. Centessa is developing orexin receptor 2 agonists for sleep-wake disorders, with lead candidate cleminorexton showing promising results in Phase 2a studies across narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. The acquisition expands Lilly's neuroscience portfolio into sleep medicine. Contingent payments are tied to FDA approvals of cleminorexton or ORX142 by 2030. The transaction, structured as a scheme of arrangement, requires shareholder approval and is expected to close in the third quarter.